Alveus Therapeutics launched with about $160 million in Series A funding to advance a Phase‑2 ready dual-agonist obesity candidate that targets the same two pathways as Amgen’s MariTide, while pursuing additional amylin-targeting molecules. The financing positions Alveus to enter Phase 2 and to compete in a crowded, high‑value obesity therapeutics market dominated by GLP‑1 and dual‑agonist drugs. Alveus says its lead program may offer dosing or tolerability advantages; investors included names active in metabolic and obesity R&D. The round underscores continued venture interest in next‑generation incretin and amylin therapeutics despite questions about long-term adherence and weight regain after drug discontinuation. The startup will use funds to complete Phase 2 planning and to expand preclinical work on second‑generation candidates that could compete with drugs from Roche, Novo Nordisk and Amgen.